Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lexapro for Autonomic Reactivity in Veterans with PTSD
NCT01271244Phase 4
Key facts
- Status
- Completed
- Start
- Jun 2008
- Primary completion
- Jun 2013
- Countries
- 1
- Sponsor
- VA Nebraska-Western Iowa Health Care System
- Modality
- Small Molecules
- Drugs
- escitalopram
- Conditions
- post-traumatic stress disorder (PTSD)major depressive disorder (MDD)
01
Overview
Phase 4, open-label trial of escitalopram in post-traumatic stress disorder (PTSD) and major depressive disorder (MDD), sponsored by VA Nebraska-Western Iowa Health Care System. Primary endpoints: High Frequency Heart Rate Variability at 12 weeks and QT Interval Variability at 12 weeks. Started Jun 2008; status: completed.
02
Design
- Study design
- Non-randomizedOpen-label
03
Who it enrols
Veterans aged 19-55 with PTSD or Major Depression, excluding those with cardiovascular issues, bipolar disorder, schizophrenia, or high suicide risk.
04
Endpoints
Primary
High Frequency Heart Rate Variability
QT Interval Variability
Beyond the preview
Go deeper on NCT01271244.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01271244.